Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- University of Chicago
- Study ID
- NCT04361708
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Pancreatic Adenocarcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Oxaliplatin — DRUGOxaliplatin will be administered on day 1 of each cycle at 85mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
- Docetaxel — DRUGDocetaxel will be administered on day 1 of each cycle at 25mg at dose level 1; 37.5 at dose level 2. The drugs will be given through the patient's Mediport.It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
- Leucovorin — DRUGLeucovorin will be administered on day 1 of each cycle at 400mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
- Irinotecan — DRUGIrinotecan will be administered on day 1 of each cycle at 120mg/m2 for low risk group, 105mg/m2 for intermediate risk group, 45mg/m2 for high risk group . The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
- 5-Fluorouracil — DRUG5-FU is given as a continuous intravenous infusion over 2 days. Patient can receive the 2-day infusion as an outpatient. On day 3 of each cycle, the patient will return to the infusion center to have the infusion hook-up disconnected.
Study Details
The purpose of the proposed study is to establish the safety of combining irinotecan chemotherapy with 5-FU, leucovorin/folinic acid, oxaliplatin, and docetaxel (abbreviated as the I-FLOAT study of gFOLFOXIRITAX) chemotherapies (leucovorin/folinic acid is a vitamin to make 5-FU work well).
Key Dates
- Start date
- May 8, 2020
- Status verified
- Sep 2025
- Primary completion
- Jun 30, 2026
- Completion
- May 31, 2027
Study Design
- Enrollment
- 54 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: High Risk UGT1A1 genotype
- Experimental: Intermediate Risk UGT1A1 genotype
- Experimental: Low Risk UGT1A1 genotype
Primary Outcome Measure
The maximum dose tolerated [ Time Frame: 1 month ]
Central Contacts
- Daniel Catenacci, MD773-702-7596
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The University of Chicago | Chicago | Illinois | 60637 | Daniel Catenacci, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Chicago, IL
By condition
By specialty
By research site
Related Studies
- A Study of Sigvotatug Vedotin in Advanced Solid TumorsPHASE1 · Recruiting · Seagen, a wholly owned subsidiary of Pfizer · Anchorage, Alaska
- Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionPHASE1 · Recruiting · Bristol-Myers Squibb · Phoenix, Arizona
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionRecruiting · Alliance for Clinical Trials in Oncology · Anchorage, Alaska
- A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerPHASE1 · Recruiting · Astellas Pharma Global Development, Inc. · Orange, California